0.905
0.04 (5.11%)
| Previous Close | 0.861 |
| Volume | 30,140 |
| Price / Book | 4.81 |
| 52 Weeks Range |
| Operating Margin (TTM) | -281,733.35% |
| Diluted EPS (TTM) | -2.14 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 113.62% |
| Current Ratio (MRQ) | 0.360 |
| Operating Cash Flow (TTM) | -8.11 M |
| Levered Free Cash Flow (TTM) | -5.33 M |
| Return on Assets (TTM) | -218.06% |
| Return on Equity (TTM) | -737.89% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | BioCardia, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 1.3 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Relative Valuation | NA |
| Financial Health | -3.9 |
| Macro Environment | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.90 |
Select this tab to load the latest available analysis.
|
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 21.66% |
| % Held by Institutions | 4.75% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Pingora Partners Llc | 30 Jun 2026 | 120,382 |
| Brown Advisory Inc | 30 Jun 2026 | 35,538 |
| Wealth Enhancement Advisory Services, Llc | 30 Sep 2026 | 18,500 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |